

**Funded Study: Treatment of Canine Lymphoma**

University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory

**Study Title:** Assessing the Efficacy and Tolerability of Daunomustine in Dogs with Multicentric Lymphoma

**Purpose of Study:** The purpose of this study is to evaluate the safety and anti-cancer activity of a novel chemotherapy, daunomustine, in treatment naïve dogs with multicentric lymphoma.

**Inclusion Criteria:**

- Dogs with confirmed (cytology or histopathology) lymphoma diagnosis with a phenotype diagnosis as well
- Dogs must be in good overall condition with adequate organ function and have no other serious illness
- NO treatment with anticancer therapies (radiation or chemotherapy) or steroid therapy

**Eligibility Diagnostics:**

Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed in their dog:

- 1) Diagnosis of lymphoma with histopathology or cytology, if not already documented
- 2) Immunophenotyping of diagnosed lymphoma
- 3) Screening blood work and urinalysis, if not performed within 7 days, must meet trial parameters
- 4) Baseline echocardiogram

**Treatment:**

Upon meeting eligibility requirements, the patient will then receive up to 5 total doses of daunomustine (depending on response), given every 21 days. Daunomustine will be given intravenously over 20 minutes. The patient will have full blood work at days 3, 7, and 14 to monitor for toxicity and will receive the next dose on day 21. Following the second dose, the patient will then be seen every 3 weeks for treatment and full blood work. After the 5<sup>th</sup> dosage, patients will return to the hospital monthly for an exam and lymph node palpation until progressive disease, or for one year, whichever occurs first. For those visits, full blood work will be repeated at every third visit, and an echocardiogram will be performed at the three-month follow-up visit. A subset of patients will be recruited for a pharmacokinetic study. In those patients, an intravenous peripheral catheter will be placed for repeated blood draws after administration of one dose of daunomustine. Blood will be sampled over the course of 24 hours from the indwelling catheter. Pets may go home after their last sample collection for the day and return the following morning for the 24-hour sample collection, or they can be hospitalized and picked up the following day.

**Compensation:**

Owner costs will include initial exam, blood work, diagnosis and phenotyping, and baseline echocardiogram. Owners will also be responsible for the cost of treating any unrelated medical conditions (such as routine ear infections). Pet owners will not be responsible for any costs associated with the normal course of treatment, or for the treatment of any complications that may arise (up to \$2000 worth of hospitalization or supportive care).

**Contact Information:**

Please feel free to contact our Clinical Trials Coordinator, Rebecca Kameron, at (217) 300-6453 or [rmoss81@illinois.edu](mailto:rmoss81@illinois.edu) to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.